Cargando…
Methylated arsenic metabolites bind to PML protein but do not induce cellular differentiation and PML-RARα protein degradation
Arsenic trioxide (As(2)O(3)) is one of the most effective therapeutic agents used for patients with acute promyelocytic leukemia (APL). The probable explanation for As(2)O(3)-induced cell differentiation is the direct targeting of PML-RARα oncoprotein by As(2)O(3), which results in initiation of PML...
Autores principales: | Wang, Qian Qian, Zhou, Xin Yi, Zhang, Yan Fang, Bu, Na, Zhou, Jin, Cao, Feng Lin, Naranmandura, Hua |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4694856/ https://www.ncbi.nlm.nih.gov/pubmed/26213848 |
Ejemplares similares
-
Regulation of NF-κB by PML and PML-RARα
por: Ahmed, Abrar, et al.
Publicado: (2017) -
The limited contribution of DNA methylation to PML-RARα induced leukemia
por: Rohde, Christian, et al.
Publicado: (2013) -
Targeting the Acute Promyelocytic Leukemia-Associated Fusion Proteins PML/RARα and PLZF/RARα with Interfering Peptides
por: Beez, Sabine, et al.
Publicado: (2012) -
PML isoforms in response to arsenic: high-resolution analysis of PML body structure and degradation
por: Hands, Katherine J., et al.
Publicado: (2014) -
The p97/VCP segregase is essential for arsenic-induced degradation of PML and PML-RARA
por: Jaffray, Ellis G., et al.
Publicado: (2023)